Envista Holdings Corp at JPMorgan Healthcare Conference Transcript
Perfect. Hello, everyone. Good afternoon. This is Rachel Vatnsdal with the life science tools and diagnostics team here at JPMorgan. Today, we're going to have Envista's presentation. As is typical with most of these breakout sessions that you've been in, it'll be 20 minutes of a presentation and then roughly 20 minutes of Q&A. So with that, I will invite Amir and Stephen up to the podium.
Thanks for having us here. This is over 4 years since we have been independent as an independently publicly traded company. I wanted to give you a quick status update of our transformation, where we are and what to expect moving forward. You all are familiar with that. I'm not going to read it. Simply put, that we are keeping the 2023 guidance that we had provided before with us intact. We are working through it. It's been a challenging year. A lot happened during 2023. We've been able to manage through it. But when
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |